Loading...
Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Loading...
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
Psychotria viridis
Arbuste contenant de la DMT utilisé comme adjoint d’Ayahuasca ; il n’est actif qu’en combinaison avec Banisteriopsis caapi.
Psychotria viridis is a shrub native to the Amazon, traditionally used as an admixture in ayahuasca preparations. Its primary active compound is N,N-dimethyltryptamine (DMT), a potent psychedelic, and it is under investigation for therapeutic applications in depression and PTSD. The plant also contains bufotenin and beta-carbolines, which contribute to its psychoactive profile.
DMT acts primarily as a partial agonist at serotonin 5-HT2A receptors, inducing profound alterations in perception and cognition. Beta-carbolines such as harmine inhibit monoamine oxidase A (MAO-A), preventing the rapid degradation of DMT in the gut and allowing oral bioavailability. Additionally, DMT interacts with sigma-1 receptors and may promote neuroplasticity through modulation of the mTOR pathway. The combination of these mechanisms underlies the entheogenic and potential therapeutic effects.
Arbuste contenant de la DMT utilisé comme adjoint d’Ayahuasca ; il n’est actif qu’en combinaison avec Banisteriopsis caapi.
Psychotria viridis is a shrub native to the Amazon, traditionally used as an admixture in ayahuasca preparations. Its primary active compound is N,N-dimethyltryptamine (DMT), a potent psychedelic, and it is under investigation for therapeutic applications in depression and PTSD. The plant also contains bufotenin and beta-carbolines, which contribute to its psychoactive profile.
DMT acts primarily as a partial agonist at serotonin 5-HT2A receptors, inducing profound alterations in perception and cognition. Beta-carbolines such as harmine inhibit monoamine oxidase A (MAO-A), preventing the rapid degradation of DMT in the gut and allowing oral bioavailability. Additionally, DMT interacts with sigma-1 receptors and may promote neuroplasticity through modulation of the mTOR pathway. The combination of these mechanisms underlies the entheogenic and potential therapeutic effects.